These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

297 related articles for article (PubMed ID: 31776591)

  • 1. Therapeutic Antibody Engineering and Selection Strategies.
    Ministro J; Manuel AM; Goncalves J
    Adv Biochem Eng Biotechnol; 2020; 171():55-86. PubMed ID: 31776591
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phage display-derived human antibodies in clinical development and therapy.
    Frenzel A; Schirrmann T; Hust M
    MAbs; 2016 Oct; 8(7):1177-1194. PubMed ID: 27416017
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Monoclonal antibodies: technologies for early discovery and engineering.
    Kennedy PJ; Oliveira C; Granja PL; Sarmento B
    Crit Rev Biotechnol; 2018 May; 38(3):394-408. PubMed ID: 28789584
    [TBL] [Abstract][Full Text] [Related]  

  • 4.
    André AS; Moutinho I; Dias JNR; Aires-da-Silva F
    Front Microbiol; 2022; 13():962124. PubMed ID: 36225354
    [TBL] [Abstract][Full Text] [Related]  

  • 5. New horizons in therapeutic antibody discovery: opportunities and challenges versus small-molecule therapeutics.
    Smith AJ
    J Biomol Screen; 2015 Apr; 20(4):437-53. PubMed ID: 25512329
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Selection of Recombinant Human Antibodies.
    Tomszak F; Weber S; Zantow J; Schirrmann T; Hust M; Frenzel A
    Adv Exp Med Biol; 2016; 917():23-54. PubMed ID: 27236551
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Introduction to antibody engineering and phage display.
    Watkins NA; Ouwehand WH
    Vox Sang; 2000; 78(2):72-9. PubMed ID: 10765141
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Engineered antibodies take center stage.
    Huston JS; George AJ
    Hum Antibodies; 2001; 10(3-4):127-42. PubMed ID: 11847424
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Affinity maturation of phage display antibody populations using ribosome display.
    Groves MA; Nickson AA
    Methods Mol Biol; 2012; 805():163-90. PubMed ID: 22094806
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Development of therapeutic antibodies for the treatment of diseases.
    Lu RM; Hwang YC; Liu IJ; Lee CC; Tsai HZ; Li HJ; Wu HC
    J Biomed Sci; 2020 Jan; 27(1):1. PubMed ID: 31894001
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phage Display Technology for Human Monoclonal Antibodies.
    Dal Ferro M; Rizzo S; Rizzo E; Marano F; Luisi I; Tarasiuk O; Sblattero D
    Methods Mol Biol; 2019; 1904():319-338. PubMed ID: 30539478
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Engineering antibodies by yeast display.
    Boder ET; Raeeszadeh-Sarmazdeh M; Price JV
    Arch Biochem Biophys; 2012 Oct; 526(2):99-106. PubMed ID: 22450168
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bacterial display in combinatorial protein engineering.
    Löfblom J
    Biotechnol J; 2011 Sep; 6(9):1115-29. PubMed ID: 21786423
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An overview on display systems (phage, bacterial, and yeast display) for production of anticancer antibodies; advantages and disadvantages.
    Mahdavi SZB; Oroojalian F; Eyvazi S; Hejazi M; Baradaran B; Pouladi N; Tohidkia MR; Mokhtarzadeh A; Muyldermans S
    Int J Biol Macromol; 2022 May; 208():421-442. PubMed ID: 35339499
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Isolation of high-affinity, neutralizing anti-idiotype antibodies by phage and ribosome display for application in immunogenicity and pharmacokinetic analyses.
    Chin SE; Ferraro F; Groves M; Liang M; Vaughan TJ; Dobson CL
    J Immunol Methods; 2015 Jan; 416():49-58. PubMed ID: 25449532
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antigen selection from an HIV-1 immune antibody library displayed on yeast yields many novel antibodies compared to selection from the same library displayed on phage.
    Bowley DR; Labrijn AF; Zwick MB; Burton DR
    Protein Eng Des Sel; 2007 Feb; 20(2):81-90. PubMed ID: 17242026
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Historical development of monoclonal antibody therapeutics.
    Nissim A; Chernajovsky Y
    Handb Exp Pharmacol; 2008; (181):3-18. PubMed ID: 18071939
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mammalian cell display for the discovery and optimization of antibody therapeutics.
    Bowers PM; Horlick RA; Kehry MR; Neben TY; Tomlinson GL; Altobell L; Zhang X; Macomber JL; Krapf IP; Wu BF; McConnell AD; Chau B; Berkebile AD; Hare E; Verdino P; King DJ
    Methods; 2014 Jan; 65(1):44-56. PubMed ID: 23792919
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Overview on the use of therapeutic antibodies in drug discovery.
    Roguska M; Kaymakcalan Z; Salfeld J
    Curr Protoc Pharmacol; 2005 Jan; Chapter 9():Unit 9.7. PubMed ID: 22294129
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Therapeutic antibody engineering by high efficiency cell screening.
    Doerner A; Rhiel L; Zielonka S; Kolmar H
    FEBS Lett; 2014 Jan; 588(2):278-87. PubMed ID: 24291259
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.